当前位置：首页 > 文献互助 > 互助详情

Innovative CAR-T therapy destroys cancer cells without dangerous side effects复制

用户knRivKc3-0Jc 1个月前 71 10 已完结

1. 系统已在2026-03-23 17:29:59对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1038/d41586-026-00358-6复制

文献链接: https://www.nature.com/articles/d41586-026-00358-6复制

其他信息:

出版社: Springer Science and Business Media LLC
作者: Rachel Fieldhouse
全文下载地址: https://www.nature.com/articles/d41586-026-00358-6.pdf

上一篇：Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

下一篇：Association of D-dimer and Fibrinogen Levels with Stroke Severity in Acute Ischemic Stroke Patients: A Cross-Sectional Study at a Tertiary Referral Hospital in …

互助时间线

2026-03-16 18:05:28 [完结求助]

楼主确认了追梦者202应助的文件是正确的, 求助状态变成 已完结

2026-03-16 17:29:59 [上传文件]

追梦者202上传了文件(pdf 193.35 KB), 求助状态变成 待确认

2026-03-16 16:59:37 [发起求助]

最新发布的求助

Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual Inhibitors 37分钟前
Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer 1小时前
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent Binders 1小时前
AutoLead: An LLM-Guided Bayesian Optimization Framework for Multi-Objective Lead Optimization 1小时前
Voltage-Gated Sodium Channels in Pain: Which Channels, Which Blockers, and Where NaV1.7 Fits 4小时前
Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC) 5小时前
Rhabdomyosarcoma spheroids with central proliferation and differentiation 5小时前
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial 5小时前
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort 5小时前
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs 5小时前
BPI26-027: Multidisciplinary Practice Patterns in HER2-Mutant NSCLC: Insights to Inform Precision Oncology Education 5小时前
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer 6小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com